KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE

SYDNEY,Feb. 7,2022 -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA),an oncology-focused drug development company,is pleased to announce that CEO,Dr James Garner,will be presenting at the BIO CEO Conference,to be held in person and virtually in New York,NY,from 14-17 February 2022.

Hosted annually by the Biotechnology Innovation Organization (BIO) for over 20 years,the conference is focused on emerging public and private companies,offering a meeting place for institutional investors,industry analysts,and senior biotech executives. The conference draws biotech companies looking to make the connections needed to take their products to the next phase.

Kazia will be presenting in person on day one of the conference,Monday,14 February. The presentation will provide an update on recent progress with Kazia's two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022.

Investors can register to attend via the conference website at:-

https://www.bio.org/events/bio-ceo-investor-conference

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company,based in Sydney,Australia.

Our lead program is paxalisib,a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway,which is being developed to treat glioblastoma,the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016,paxalisib commenced recruitment to GBM AGILE,a pivotal study in glioblastoma,in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018,and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition,paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801,a small-molecule inhibitor of VEGFR3,which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

For more information,please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner,Chief Executive Officer,Managing Director.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-bio-ceo-conference-301476367.html